West Pharmaceutical Services Inc (WST) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Total Revenue Chart for West Pharmaceutical Services Inc
West Pharmaceutical Services Inc (WST) revenue for FY2025 was USD 3.1B, a 6.3% change from FY2024. West Pharmaceutical Services Inc's revenue grew from USD 190.1M in 1985 to USD 3.1B in 2025 (1516.9% over 40 years). Earnings per share grew from USD 0.03 in 2000 to USD 6.79 in 2025 (24362.6%). Revenue compound annual growth rate: 5-year CAGR of 7.4%, 10-year CAGR of 8.2%, 20-year CAGR of 7.7%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $24.53B
- Implied Share Price
- $348.60
- Enterprise Value
- $24.42B
- Revenue (TTM)
- $3.33B
- EBITDA
- $912.20M
- Profit Margin
- 16.98%
- Trailing P/E
- 45.04
- Forward P/E
- 39.53
- Price/Book (MRQ)
- 8.21
- Price/Sales (TTM)
- 7.37
- EV/EBITDA
- 27.77
- EV/Revenue
- 7.34
- Dividend Yield
- 0.25%
- Book Value
- $42.47
- Free Cash Flow (FY2025)
- $468.90M
- Free Cash Flow Yield
- 1.91%
Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.